Evidence map›Paper›PMID 42277357›Full record

ArticleScientific reports2026

A novel bicistronic vector inducing balanced alternative splicing for antibody production.

Shoutaro Tsuji

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shoutaro TsujiDepartment of Medical Technology & Clinical Engineering, Gunma University of Health and Welfare, 191-1 Kawamagari-machi, Maebashi, 371-0823, Gunma, Japan. tsuji-s@shoken-gakuen.ac.jp.

Funding

Japan Agency for Medical Research and Development JP25ae0121009
6 · The paper itself

Abstract

Efficient and stable production of recombinant monoclonal antibodies requires sufficient expression of light (LC) and heavy (HC) chains within host cells. Conventional bicistronic systems such as internal ribosome entry site (IRES)- or 2 A peptide-based vectors often suffer from imbalanced translation efficiencies or the presence of residual peptide tags that can compromise antibody quality. We developed a novel bicistronic expression platform, designated the cassette exon-associated (CAE) system, which exploits alternative splicing derived from the HEG1 gene to generate two mRNA isoforms from a single promoter. The CAE cassette contains synthetic splice donor and acceptor sequences that enable expression of LC and HC without additional peptide sequences. The optimized construct, pCAE3.31, driven by various promoters-including chicken β-actin, cytomegalovirus, and human elongation factor-1α-efficiently expressed functional antibodies in multiple mammalian cell lines. Compared with IRES-based systems, the CAE vector achieved an 8-fold higher antibody yield. Fab fragments were also produced using the CAE system. The CAE system represents a compact and versatile bicistronic expression strategy that ensures expression of LC and HC, avoids extraneous peptide fusion, and is compatible with major mammalian promoters. This platform facilitates efficient production of recombinant antibodies and Fab fragments, supporting screening and potential therapeutic applications.

Indexed as

Alternative SplicingAntibodies, MonoclonalGenetic VectorsAnimalsCHO CellsCricetulusCytomegalovirusHEK293 CellsHumansImmunoglobulin Fab FragmentsImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsPeptide Elongation Factor 1Promoter Regions, GeneticRecombinant ProteinsAntibodies, MonoclonalImmunoglobulin Fab FragmentsImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsPeptide Elongation Factor 1Recombinant ProteinsAlternative splicingBicistronic expressionCassette exonCHO cellsHEG1Recombinant antibody

Identifiers

PMID42277357
PMCPMC13503707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.